# Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia

> **NCT00703300** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 19 (actual)

## Conditions studied

- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Recurrent Adult Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia
- Untreated Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** bortezomib
- **DRUG:** decitabine
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00703300
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2010-03
- **Final completion:** 2014-10
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2014-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00703300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00703300, "Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00703300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*